AHA again urges HHS to protect 340B program from drug companies’ actions

Sep 08, 2020 - 02:39 PM
AHA-OIG-letter

The AHA again expressed concern to the Department of Health and Human Services about recent actions taken by several major drug manufacturers to limit the distribution of certain 340B drugs to hospitals. 

While the Health Resources and Services Administration, which oversees the 340B program, is investigating these activities, AHA urged HHS to take “swift and decisive action to halt these pernicious tactics” to prevent other manufacturers from following suit.

“The drug companies are attempting to exploit for their financial benefit the current COVID-19 health care crisis,” AHA said. “As you are aware, hospitals throughout the nation are under severe stress by the need to prepare for, and/or care for, COVID-19 patients, while coping with the financial damages inflicted by the virus. Therefore, we urge you to act immediately against any drug manufacturer employing these pernicious tactics to ensure that 340B drugs are available and accessible to vulnerable communities.” Read the full letter here.

The AHA has engaged in numerous efforts urging the drug companies to cease these activities and have HHS take action to protect 340B hospitals. See the previous letters the AHA has sent on the issue:

Related News Articles

Headline
Senators introduce bipartisan 340B legislation
A bipartisan group of senators Aug. 5 introduced the Supporting Underserved and Strengthening Transparency, Accountability and Integrity Now and for the Future…
Headline
HHS announces revised 340B Rebate Model Pilot Program; see AHA’s statement shared with media 
The Department of Health and Human Services today issued a notice announcing a revised 340B Rebate Model Pilot Program, allowing qualifying drug manufacturers…
Headline
Court rules that companies may not impose 340B rebate model without HHS approval
The U.S. District Court for the District of Columbia July 21 upheld a lower court’s decision that Section 340B of the Public Health Service Act does not …
Headline
AHA challenges HRSA’s burden estimate for proposed 340B rebate model
The AHA July 14 urged the Health Resources and Services Administration to revise its estimate of the administrative burden associated with the agency’s…
Headline
AHA urges court to reject AbbVie bid to change 340B program rules
The AHA today filed a friend-of-the-court brief supporting the Department of Health and Human Services’ motion to dismiss AbbVie’s lawsuit …
Headline
HRSA announces 340B program sales reached $100 billion in CY 2025
The Health Resources and Services Administration announced that 340B covered entities purchased $100 billion in outpatient drugs under the federal 340B Drug…